BAK1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population designed to disrupt the BAK1 gene, encoding a pro-apoptotic BCL-2 family member. This polyclonal pool contains heterogeneous CRISPR-induced mutations, providing a robust loss-of-function model for studying intrinsic apoptosis without clonal selection bias. The product enables investigation of BAK1-dependent cell death mechanisms and evaluation of therapeutics targeting the mitochondrial apoptosis pathway.
HAP1 is a near-haploid human cell line derived from chronic myeloid leukemia, serving as a myeloid progenitor model. Its haploid karyotype facilitates efficient CRISPR/Cas9-mediated gene disruption and ensures clear genotype-phenotype correlations, making it a favored platform for functional genomics and apoptosis research. The CML origin provides a disease-relevant background for studying hematopoietic malignancies and drug resistance.
BAK1 functions as a critical mitochondrial apoptosis effector, normally restrained by anti-apoptotic BCL-2, BCL-XL, and MCL-1. Upon apoptotic signaling, BH3-only proteins (tBID, BIM, PUMA, NOXA) relieve this inhibition, enabling BAK1 to oligomerize with BAX at the outer mitochondrial membrane, a process facilitated by VDAC2. This permeabilization releases cytochrome c, triggering APAF1-mediated caspase-9 activation, followed by executioner caspase-3/7 cleavage. Thus, BAK1 operates downstream of diverse stress signals and upstream of caspase cascades, controlling the commitment point for mitochondrial outer membrane permeabilization.
Disruption of BAK1 in HAP1 cells abrogates mitochondrial apoptosis, conferring resistance to intrinsic death stimuli. This knockout model permits dissection of BAK1-specific roles independent of BAX and exploration of compensatory survival mechanisms. The polyclonal background avoids clonal artifacts, ensuring a representative population response. It is particularly useful for screening BH3 mimetics like ABT-737 and identifying synthetic lethal interactions in a near-haploid leukemia context.
Key applications include apoptosis mechanism studies using cytochrome c release, caspase-3/7 activity, and Annexin V assays; flow cytometric analysis of mitochondrial membrane potential (JC-1); and co-immunoprecipitation to probe BAK1 interactions with BCL-2 or VDAC2. These cells support validation of BCL-2 family inhibitors, BH3 profiling, and genetic screens for apoptosis regulators in cancer and neurodegenerative disease models. For additional information on cell culture, quality control, or custom engineering, contact Ascent Research.
